Showing results (261-270 of 380) with videos related to
Sort By:
Pageof 38
Journal of Translational Medicine|November 7, 2015
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanomaLisa Zimmer, Thomas K Eigentler, Felix Kiecker, et al.Journal of Clinical Medicine|May 16, 2020
Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional TrialTheresa Steeb, Anja Wessely, Dagmar von Bubnoff, et al.Frontiers in Immunology|January 19, 2024
MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detectionMarten Meyer, Christina Parpoulas, Titouan Barthélémy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibitionLisa Zimmer, Uwe Hillen, Elisabeth Livingstone, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 PatientsTakami Sato, Marcus O Butler, Sophie Piperno-Neumann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled AnalysisSandra P D'Angelo, James Larkin, Jeffrey A Sosman, et al.European Journal of Cancer (Oxford, England : 1990)|March 31, 2021
Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalitiesEleftheria Chorti, Sied Kebir, Misbah S Ahmed, et al.Journal for Immunotherapy of Cancer|July 7, 2022
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanomaInes Pires da Silva, Danny Zakria, Tasnia Ahmed, et al.JAMA Oncology|December 4, 2015
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune DisordersDouglas B Johnson, Ryan J Sullivan, Patrick A Ott, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2025
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic MelanomaReinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.Pageof 38